Company intelligence / Profile preview
Othera Pharmaceuticals, Inc.
Exton, Pennsylvania, USAothera.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Completed Phase 2 trial of OT-551 for geographic atrophy (an advanced form of dry AMD) with positive interim results announced in April 2009. Also conducted Phase 1/2 evaluation of OT-730 ophthalmic solution for reducing intraocular pressure in subjects with ocular hypertension or open-angle glaucoma.
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Othera Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Othera Pharmaceuticals, Inc..